Kymera Therapeutics has signed a deal with Gilead Sciences to develop molecular glue degraders targeting cyclin-dependent kinase 2 (CDK2) for solid tumors including breast cancer, potentially earning up to $750 million. Concurrently, its partnership with Sanofi shifts focus as Sanofi progresses a different IRAK4 degrader, KT-485, into clinical testing after discontinuing a prior candidate. These moves reflect Kymera’s strategic repositioning in protein degradation therapeutics for oncology and immunology indications.